Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 16 Precursor Cell Lymphoblastic Leukemia-Lymphoma 15 Recurrence 13 Multiple Myeloma 12 Lymphoma, B-Cell 12 Lymphoma, Non-Hodgkin 9 Leukemia, Lymphocytic, Chronic, B-Cell 8 Ovarian Neoplasms 7 Lymphoma 7 Burkitt Lymphoma 7 Melanoma 5 Lymphoma, Mantle-Cell 5 Hematologic Neoplasms 5 Nasopharyngeal Carcinoma 4 Myelodysplastic Syndromes 4 Lymphoma, T-Cell 4 Leukemia 3 Graft vs Host Disease 3 Uterine Cervical Neoplasms 2 Sarcoma, Synovial 2 Neuroblastoma 2 Neoplasms, Plasma Cell 2 Neoplasms 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, Follicular 2 Lung Neoplasms 2 Leukemia, T-Cell 2 Hodgkin Disease 2 Head and Neck Neoplasms 2 Glioblastoma 2

Interventions

Granulocyte-Macrophage Colony-Stimulating Factor 2 Colony-Stimulating Factors 2 fludarabine 1 camrelizumab 1 Radiofrequency Ablation 1 Interleukin-2 1 Immune Checkpoint Inhibitors 1 Cyclophosphamide 1 Adjuvants, Immunologic 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Advanced Malignant Solid Tumor × fludarabine × Clear all

NCT03171220 2017-06-06

NRT-01

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 1/2 Unknown

Other solid neoplasm

Advanced Malignant Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡